Regorafenib in combination with temozolomide with or without radiotherapy in patients with newly diagnosed MGMT-Methylated, IDH wild-type glioblastoma. A phase I dose-finding study (REGOMA-2).
REGOMA-2
Phase 1 other active
Quick answer
Regorafenib in combination with temozolomide with or without radiotherapy in patients with newly diagnosed MGMT-Methylated, IDH wild-type glioblastoma. A phase I dose-finding study (REGOMA-2). for MGMT-Methylated, IDH wild-type glioblastoma is a Phase 1 program (other) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Istituto Gentili S.r.l.
- Indication
- MGMT-Methylated, IDH wild-type glioblastoma
- Phase
- Phase 1
- Modality
- other
- Status
- active